Harvard Health Blog

Bleeding risk from new blood thinner Pradaxa higher than first reported

Posted November 05, 2014, 12:34 pm Howard LeWine, M.D., Chief Medical Editor, Internet Publishing, Harvard Health Publications The FDAs approval in 2010 of the blood-thinner dabigatran (Pradaxa) got many doctors excited. This drug got the green light after a head-to-head trial with warfarin (generic, Coumadin) in people with an irregular heart beat from atrial fibrillation. …

To continue reading this article you must be registered.

Get Licensed Content to Harvard Health

If you are interested in licensing content from Harvard Health Publications, please contact us using our online form. Our licensing and business development professionals will help you leverage consumer health content from Harvard Medical School as a clear differentiator in helping achieve your business goals.

Contact Us

Customer Log In